While still considered a rare disease, transthyretin amyloid cardiomyopathy (ATTR-CM) is nevertheless emerging in more people than previously thought due to increased interest and improved access to ...

A recent study led by a team of researchers at The Johns Hopkins University School of Medicine examining aging mice has provided what is believed to be the first evidence that amyloid beta ...

How is it possible to spend tens of billions of dollars developing drugs to treat a serious disease that affects millions of people, and yet end up with something that does not work? This is a mystery ...

Researchers have now proposed a molecular mechanism that links amyloid deposition in the aortic valve with degenerative calcification. They also theorize that other risk factors for CAVD, such as high ...

Researchers at Niigata University have used advanced three-dimensional (3D) imaging to reveal how amyloid β (Aβ) deposits spread along blood vessels in the human brain in cerebral amyloid angiopathy ...

AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...

Transthyretin amyloidosis (ATTR) is a rare, progressive and highly aggressive degenerative disease. It is caused by the misfolding of a specific protein, leading to its toxic accumulation in the form ...

Learn why genetic testing is vital for ATTR-CM diagnosis, how it identifies hereditary risks for family members, and the ...